- Nervousness

- Memory impairment

-Sleep disorder
 - Suicide

- Suicide attempt

- Suicidal ideation

Nervous system disorders
 - Headache
 - Dysgeusia
 - Neuropathy

- Dizziness

- Hypoasthesia

- Parasthesia

- Tremor

- Somnolence
- Coma

- Cerebrovascular accident

- Convulsions
- Transient erectile dysfunction
-Encephalopathy
 
Eye disorders

- Visual disturbance

- Conjunctivitis
- Ischemic retinopathy
- Retinal artery thrombosis

- Optic neuropathy

- Retinal hemorrhage

- Retinal vein thrombosis

- Retinal exudates

- Retinopathy

- Papilledema

Ear and labyrinth disorders
 
- Vertigo
 
Cardiac disorders
 
 - Arrhythmias4

- Palpitations

-Cyanosis
 
 - Cardiorespiratory arrest

- Myocardial infarction

- Congestive heart failure

- Pulmonary edema

Vascular disorders

- Hypertension

- Hypotension
- Vasculitis

Respiratory, thoracic and mediastinal disorders

- Dyspnea

- Cough

Gastrointestinal disorders
 - Diarrhea
 - Vomiting

-Abdominal pain

- Nausea

-Dry mouth
 
 - Pancreatitis

- Intestinal hypermotility

- Constipation

- Dyspepsia

- Flatulence
 - Reactivation of peptic ulcer

-gastrointestinal bleeding (non life threatening)

Hepato-biliary disorders

- Hepatic failure

- Hepatitis

- Hepatic dysfunction

Skin and subcutaneous tissue disorders
 - Alopecia5

- Sweating increased
 
 - Psoriasis6

- Pruritus
 - Rash

- Dry skin

- Epistaxis

- Mucosal dryness

- Rhinorrhea

Musculoskeletal, connective tissue and bone disorders
 - Myalgia

- Arthralgia
 
 
 - Systemic lupus

erythematosus

- Arthritis

Renal and urinary disorders
 
 
 - Proteinuria

- Increased cell count in urine
 - Acute renal failure7

- Renal impairment

General disorders and administration site conditions
 -Flu like illness

-Appetite decreased

-Pyrexia

-Rigors

-Fatigue
 - Chest pain

- Edema
 
-Injection site necrosis

-Injection site reaction

Investigations
 
 - weight loss
 -Increased ALT

-Increased transaminase

-Increased blood alkaline phosphatase
 - Increased blood creatinine

-Increased blood urea

- Increased blood bilirubin

- Increased blood uric acid

-Increased blood LDH

1(including exacerbations of herpes labialis)

2In myelosuppressed patients, thrombocytopenia and decreased haemoglobin occurred more frequently. Recovery of severe haematological deviations to pre-treatment levels usually occurred within seven to ten days after discontinuing Roferon-A treatment.

3(e.g. urticaria, angioedema, bronchospasm and anaphylaxis)

4including atrioventricular block

5(reversible upon discontinuation; increased hair loss may continue for several weeks after end of treatment)

6exacerbation of, or provocation of psoriasis

7(mainly in cancer patients with renal dis